BMS 986231

Drug Profile

BMS 986231

Alternative Names: BMS-986231; BMS-986231-01; CXL 1427; HNO Donor; HNO Nitroxyl Donor

Latest Information Update: 04 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cardioxyl Pharmaceuticals
  • Developer Bristol-Myers Squibb
  • Class Heart failure therapies
  • Mechanism of Action Nitric oxide donors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute heart failure

Most Recent Events

  • 30 Nov 2017 Bristol-Myers Squibb plans a phase II trial for Heart failure in the UK, USA and Japan , (NCT03357731)
  • 14 Nov 2017 Bristol-Myers Squibb plans a phase II/III trial for Cardiovascular disease
  • 09 Nov 2017 Bristol-Myers Squibb plans a phase I trial in patients with different levels of kidney function in Czech Republic and Poland in December 2017 (NCT03332186)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top